Skip to content

Study · Case report or series · n = 1 · 2024

4 results

Clinically Meaningful Outcomes after 1 Year of Treatment with Setmelanotide in an Adult Patient with a Variant in SH2B1.

Politei JM, Patrono A

Obesity facts16 Sept 2024Cited by 3 (Europe PMC)

PMID39284294 (opens in a new tab)PMCIDPMC11661841 (opens in a new tab)DOI10.1159/000541267 (opens in a new tab)PepBankPUB-39284294
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    An adult with an SH2B1 variant lost 5.4% body weight after three months of setmelanotide treatment.

    In plain wordsAn adult with an SH2B1 variant lost 5.4% body weight after three months of setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    DecreaseWeight loss after three months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Measurements

    Body weight loss
    5.4%
    After 3 months of setmelanotide treatment

    Source sentences

    Summary
    After 3 months of treatment, our patient lost 5.4% of body weight.
    1 context sentence
    Summary · context
    We describe here the clinical response after 1 year of setmelanotide treatment in a 22-year-old patient with an SH2B1 variant.
  2. 02HumanCase report or seriesEfficacy outcome

    An adult with an SH2B1 variant gained 4% body weight during a three-month period of setmelanotide noncompliance.

    In plain wordsAn adult with an SH2B1 variant gained 4% body weight during a three-month period of noncompliance with setmelanotide.

    Peptide
    Setmelanotide
    Outcome
    IncreaseWeight regain during noncompliance
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Body weight gain
    4%
    Three-month period of setmelanotide noncompliance

    Source sentences

    Summary
    This period was followed by a 3-month period of noncompliance, in which the patient gained 4% body weight.
    1 context sentence
    Summary · context
    We describe here the clinical response after 1 year of setmelanotide treatment in a 22-year-old patient with an SH2B1 variant.
  3. 03HumanCase report or seriesEfficacy outcome

    After daily setmelanotide resumed, an adult with an SH2B1 variant showed 19.5% weight reduction at the one-year treatment assessment.

    In plain wordsAfter daily setmelanotide resumed, an adult with an SH2B1 variant showed 19.5% weight loss at the one-year assessment.

    Peptide
    Setmelanotide
    Outcome
    DecreaseWeight reduction after treatment reinstatement
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Body weight reduction
    19.5%
    One-year assessment after daily treatment resumed

    Source sentences

    Summary
    After reinstating daily drug administration, the patient showed a 19.5% reduction in body weight and a clear improvement in all hunger scales after 1 year of treatment.
    1 context sentence
    Summary · context
    We describe here the clinical response after 1 year of setmelanotide treatment in a 22-year-old patient with an SH2B1 variant.
  4. 04HumanCase report or seriesEfficacy outcome

    After daily setmelanotide resumed, an adult with an SH2B1 variant improved on all hunger scales at the one-year treatment assessment.

    In plain wordsAfter daily setmelanotide resumed, an adult with an SH2B1 variant improved on all hunger scales at the one-year assessment.

    Peptide
    Setmelanotide
    Outcome
    Direction not reportedHunger scales
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After reinstating daily drug administration, the patient showed a 19.5% reduction in body weight and a clear improvement in all hunger scales after 1 year of treatment.
    1 context sentence
    Summary · context
    We describe here the clinical response after 1 year of setmelanotide treatment in a 22-year-old patient with an SH2B1 variant.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.